Holen Sie sich die Stockscreener-App
7.555
3.20%
-0.25
Handel nachbörslich:
7.55
-0.005
-0.07%
Gyre Therapeutics Inc Aktie (GYRE) Neueste Nachrichten
Gyre Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Gyre Therapeutics Stock (ISIN: KYG4200L1031) Faces Pressure After Q4 Earnings Miss Amid Pipeline Mom - AD HOC NEWS
Gyre Therapeutics Sees Stable $100 Million Lung Fibrosis Drug Revenue - marketscreener.com
Volatility Watch: Whats Gyre Therapeutics Incs historical returnTrade Performance Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
GNI Group Highlights Fibrosis Revenue Upside and Advances Degrader Pipeline via Gyre and Cullgen - TipRanks
Gyre Therapeutics (GYRE) Q4 Loss Challenges Bullish Margin Durability Narratives - simplywall.st
Gyre Therapeutics (GYRE) Posts Q4 FY25 Loss of $0.02; misses estimates - AlphaStreet
Gyre Therapeutics, Inc. (GYRE) Q4 Results Fall Short of Expectations - Bitget
Gyre Therapeutics Projects Strong Growth for Fibrosis Programs - TipRanks
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates - Yahoo Finance
Gyre Therapeutics Q4 revenue beats estimates on new product launch - TradingView
Gyre Therapeutics Swings to Net Loss in Q4, Revenue Increases - marketscreener.com
Gyre Therapeutics reports fourth quarter and full year 2025 financial results - marketscreener.com
(GYRE) Gyre Therapeutics Expects 2026 Revenue Range $100.5M to $111.0M, vs. FactSet Est of $148.0M - marketscreener.com
Earnings Flash (GYRE) Gyre Therapeutics Posts Q4 Revenue $37.2M, vs. FactSet Est of $35.4M - marketscreener.com
Earnings Flash (GYRE) Gyre Therapeutics Posts Q4 Loss $0.02 a Share, vs. FactSet Est of $0.06 EPS - marketscreener.com
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Gyre Therapeutics Reports 10% Revenue Growth in Full-Year 2025 and Announces Acquisition of Cullgen - Quiver Quantitative
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides ... - Bluefield Daily Telegraph
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire Inc.
Gyre Therapeutics (GYRE) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Earnings Update: Can Gyre Therapeutics Inc maintain its current growth rateJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap UpTime to Buy? - MarketBeat
GYRE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors - Quantisnow
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction - Yahoo Finance
GNI Group’s Gyre Therapeutics to acquire Cullgen in $300 million all-stock deal - TipRanks
Gyre, Cullgen Merge In $300M All-Stock Deal - Law360
Gyre Therapeutics (NASDAQ:GYRE) Trading Up 8.2%Should You Buy? - MarketBeat
Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead - Stocktwits
H.C. Wainwright reiterates Buy on Gyre Therapeutics stock By Investing.com - Investing.com UK
H.C. Wainwright reiterates Buy on Gyre Therapeutics stock - Investing.com Nigeria
Gyre Therapeutics to Acquire Cullgen in All-Stock Merger - TipRanks
Gyre Therapeutics (NASDAQ: GYRE) inks $300M all-stock Cullgen deal - Stock Titan
Gyre Therapeutics, Inc. Announces to Appoint Ying Luo as CEO, Effective March 2, 2026 - marketscreener.com
Gyre Therapeutics enters into agreement to acquire Cullgen to gain targeted protein degradation platform and pipeline - marketscreener.com
Gyre Therapeutics Enters Into Agreement To Acquire Cullgen To Gain Targeted Protein Degradation Platform And Pipeline - TradingView
Gyre Therapeutics to acquire Cullgen for $300 million - Investing.com
Gyre Therapeutics Enters into Agreement to Acquire Cullgen - GlobeNewswire
getLinesFromResByArray error: size == 0 - mfd.ru
Gyre Therapeutics, Inc. entered into an agreement to acquire Cullgen Inc. - marketscreener.com
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a 111% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Risks Report: Can Gyre Therapeutics Inc expand into new marketsJuly 2025 Macro Moves & Precise Swing Trade Alerts - baoquankhu1.vn
Big Picture: How do insiders feel about Gyre Therapeutics Inc2025 Valuation Update & Trade Opportunity Analysis - baoquankhu1.vn
GYREGyre Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Aug Selloffs: Can Gyre Therapeutics Inc expand into new marketsJuly 2025 Earnings & Accurate Intraday Trading Signals - baoquankhu1.vn
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Average Recommendation of “Hold” by Brokerages - Defense World
Can Gyre Therapeutics Inc. scale operations efficientlyJuly 2025 Weekly Recap & Daily Entry Point Trade Alerts - mfd.ru
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Capitalizing on a Promising 113.78% Upside - DirectorsTalk Interviews
Market Catalysts: Can Gyre Therapeutics Inc weather a recessionTreasury Yields & Daily Entry Point Trade Alerts - baoquankhu1.vn
Can Gyre Therapeutics Inc. maintain its current growth ratePortfolio Update Report & Safe Entry Zone Tips - mfd.ru
GNI Group Delays 2026 Earnings Forecast Amid Regulatory and Pipeline Uncertainty - TipRanks
High Growth Tech Stocks in US for February 2026 - simplywall.st
Will Gyre Therapeutics Inc outperform tech stocks2025 Price Action Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) Last Week's 8.5% Decline Must Have Disappointed Public Companies Who Have a Significant Stake - 富途牛牛
Returns Recap: Is TENPREs ROIC above industry averageWeekly Investment Report & Expert Curated Trade Setups - baoquankhu1.vn
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a Promising 139.68% Upside Potential - DirectorsTalk Interviews
Gyre Therapeutics slumps 16%, prices $20M stock offering - MSN
What dividend growth rate does Gyre Therapeutics Inc. offer2025 Technical Patterns & Free Expert Verified Stock Movement Alerts - mfd.ru
Analyzing Gyre Therapeutics (NASDAQ:GYRE) and ImmunityBio (NASDAQ:IBRX) - Defense World
Gyre Therapeutics, Inc. (GYRE) Investor Outlook: Eyeing a 119% Upside with a Strong Buy Consensus - DirectorsTalk Interviews
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 2.4%Still a Buy? - MarketBeat
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):